Literature DB >> 26314636

Effects of BACE1 haploinsufficiency on APP processing and Aβ concentrations in male and female 5XFAD Alzheimer mice at different disease stages.

L Devi1, M Ohno2.   

Abstract

β-Site APP-cleaving enzyme 1 (BACE1) initiates the generation of amyloid-β (Aβ), thus representing a prime therapeutic target for Alzheimer's disease (AD). Previous work including ours has used BACE1 haploinsufficiency (BACE1(+/-); i.e., 50% reduction) as a therapeutic relevant model to evaluate the efficacy of partial β-secretase inhibition. However, it is unclear whether the extent of Aβ reductions in amyloid precursor protein (APP) transgenic mice with BACE1(+/-) gene ablation may vary with sex or disease progression. Here, we compared the impacts of BACE1 haploinsufficiency on Aβ concentrations and APP processing in 5XFAD Alzheimer mice (1) between males and females and (2) between different stages with moderate and robust Aβ accumulation. First, male and female 5XFAD mice at 6-7 months of age showed equivalent levels of Aβ, BACE1, full-length APP and its metabolites. BACE1 haploinsufficiency significantly lowered soluble Aβ oligomers, total Aβ42 levels and plaque burden in 5XFAD mouse brains irrespective of sex. Furthermore, there was no sex difference in reductions of β-cleavage products of APP (C99 and sAPPβ) found in BACE1(+/-)·5XFAD mice relative to BACE1(+/+)·5XFAD controls. Meanwhile, APP and sAPPα levels in BACE1(+/-)·5XFAD mice were higher than those of 5XFAD controls regardless of sex. Based on these observations, we next combined male and female data to examine the effects of BACE1 haploinsufficiency in 5XFAD mice at 12-14 months of age, as compared with those in 6-7-month-old 5XFAD mice. Oligomeric Aβ and C99 levels were dramatically elevated in older 5XFAD mice. Although the β-metabolites of APP were significantly reduced by BACE1 haploinsufficiency in both age groups, high levels of these toxic amyloidogenic fragments remained in 12-14-month-old BACE1(+/-)·5XFAD mice. The present findings are consistent with our previous behavioral data showing that BACE1 haploinsufficiency rescues memory deficits in 5XFAD mice irrespective of sex but only in the younger age group.
Copyright © 2015 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  5XFAD; Aβ oligomers; BACE1; C99; haploinsufficiency; sex

Mesh:

Substances:

Year:  2015        PMID: 26314636      PMCID: PMC4591236          DOI: 10.1016/j.neuroscience.2015.08.037

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  68 in total

1.  A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease.

Authors:  Hiroaki Fukumoto; Hideki Takahashi; Naoki Tarui; Junji Matsui; Taisuke Tomita; Mitsuhiro Hirode; Masumi Sagayama; Ryouta Maeda; Makiko Kawamoto; Kazuko Hirai; Jun Terauchi; Yasufumi Sakura; Mitsuru Kakihana; Kaneyoshi Kato; Takeshi Iwatsubo; Masaomi Miyamoto
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

Review 2.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

3.  BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.

Authors:  Kouhei Nishitomi; Gaku Sakaguchi; Yuko Horikoshi; Audrey J Gray; Masahiro Maeda; Chiho Hirata-Fukae; Amanda G Becker; Motoko Hosono; Isako Sakaguchi; S Sakura Minami; Yoshihiro Nakajima; Hui-Fang Li; Chie Takeyama; Tsuyoshi Kihara; Akinobu Ota; Philip C Wong; Paul S Aisen; Akira Kato; Noriaki Kinoshita; Yasuji Matsuoka
Journal:  J Neurochem       Date:  2006-11-02       Impact factor: 5.372

4.  In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.

Authors:  Sethu Sankaranarayanan; Eric A Price; Guoxin Wu; Ming-Chih Crouthamel; Xiao-Ping Shi; Katherine Tugusheva; Keala X Tyler; Jason Kahana; Joan Ellis; Lixia Jin; Thomas Steele; Shawn Stachel; Craig Coburn; Adam J Simon
Journal:  J Pharmacol Exp Ther       Date:  2007-12-21       Impact factor: 4.030

Review 5.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

6.  Single App knock-in mouse models of Alzheimer's disease.

Authors:  Takashi Saito; Yukio Matsuba; Naomi Mihira; Jiro Takano; Per Nilsson; Shigeyoshi Itohara; Nobuhisa Iwata; Takaomi C Saido
Journal:  Nat Neurosci       Date:  2014-04-13       Impact factor: 24.884

7.  Soluble aβ promotes wild-type tau pathology in vivo.

Authors:  Meredith A Chabrier; Mathew Blurton-Jones; Andranik A Agazaryan; Joy L Nerhus; Hilda Martinez-Coria; Frank M LaFerla
Journal:  J Neurosci       Date:  2012-11-28       Impact factor: 6.167

8.  The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques.

Authors:  Patty C Kandalepas; Katherine R Sadleir; William A Eimer; Jie Zhao; Daniel A Nicholson; Robert Vassar
Journal:  Acta Neuropathol       Date:  2013-07-03       Impact factor: 17.088

9.  BACE1 inhibitor drugs in clinical trials for Alzheimer's disease.

Authors:  Robert Vassar
Journal:  Alzheimers Res Ther       Date:  2014-12-24       Impact factor: 6.982

10.  Amyloid-precursor-protein-lowering small molecules for disease modifying therapy of Alzheimer's disease.

Authors:  Sina Cathérine Rosenkranz; Markus Geissen; Kristina Härter; Beata Szalay; Isidro Ferrer; Jana Vogel; Stephen Smith; Markus Glatzel
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

View more
  8 in total

1.  Upregulation of Alzheimer's Disease Amyloid-β Protein Precursor in Astrocytes Both in vitro and in vivo.

Authors:  Yingxia Liang; Frank Raven; Joseph F Ward; Sherri Zhen; Siyi Zhang; Haoqi Sun; Sean J Miller; Se Hoon Choi; Rudolph E Tanzi; Can Zhang
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

Review 2.  Sex and the development of Alzheimer's disease.

Authors:  Christian J Pike
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

3.  Parvalbumin-Positive Neuron Loss and Amyloid-β Deposits in the Frontal Cortex of Alzheimer's Disease-Related Mice.

Authors:  Farhan Ali; Stephanie L Baringer; Arianna Neal; Esther Y Choi; Alex C Kwan
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

4.  Iron dysregulates APP processing accompanying with sAPPα cellular retention and β-secretase inhibition in rat cortical neurons.

Authors:  Yu-Ting Chen; Wu-Yan Chen; Xiao-Tian Huang; Ye-Chun Xu; Hai-Yan Zhang
Journal:  Acta Pharmacol Sin       Date:  2017-08-24       Impact factor: 6.150

5.  Liver X receptor-β improves autism symptoms via downregulation of β-amyloid expression in cortical neurons.

Authors:  Ji-Xiang Zhang; Jun Zhang; Ye Li
Journal:  Ital J Pediatr       Date:  2016-05-06       Impact factor: 2.638

6.  BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology.

Authors:  Finn Peters; Hazal Salihoglu; Eva Rodrigues; Etienne Herzog; Tanja Blume; Severin Filser; Mario Dorostkar; Derya R Shimshek; Nils Brose; Ulf Neumann; Jochen Herms
Journal:  Acta Neuropathol       Date:  2018-01-11       Impact factor: 17.088

7.  Meprin β knockout reduces brain Aβ levels and rescues learning and memory impairments in the APP/lon mouse model for Alzheimer's disease.

Authors:  Liana Marengo; Fred Armbrust; Caroline Schoenherr; Steffen E Storck; Ulrich Schmitt; Silvia Zampar; Oliver Wirths; Hermann Altmeppen; Markus Glatzel; Christoph Kaether; Sascha Weggen; Christoph Becker-Pauly; Claus U Pietrzik
Journal:  Cell Mol Life Sci       Date:  2022-03-02       Impact factor: 9.207

8.  3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice.

Authors:  Divna Lazic; Abhay P Sagare; Angeliki M Nikolakopoulou; John H Griffin; Robert Vassar; Berislav V Zlokovic
Journal:  J Exp Med       Date:  2019-01-15       Impact factor: 17.579

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.